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INTRODUCTION
Glucagon-like peptide 1 (GLP-1) is a 30-amino acid peptide hormone produced by enteroendocrine cells and subsets of neurons within the caudal hindbrain (Campbell and Drucker, 2013; Jin et al., 1988) . GLP-1 exerts a wide range of metabolic actions that regulate energy homeostasis through a single GLP-1 receptor (GLP-1R) (Thorens, 1992) . The GLP-1R is widely distributed in peripheral tissues, including the endocrine pancreas, lungs, stomach, intestine, kidneys, heart, and some blood vessels (Bullock et al., 1996; Campos et al., 1994; Thorens, 1992) . Hence, current concepts of GLP-1 biology invoke direct actions of GLP-1 acting as a circulating hormone to enable the metabolic activities ascribed to GLP-1R signaling (Campbell and Drucker, 2013) .
The classical endocrine concept of GLP-1 biology has been challenged by observations that plasma concentrations of GLP-1 are extremely low, raising questions about whether the metabolic actions of GLP-1 are mediated via its envisioned role as a circulating hormone (Chambers et al., 2017; D'Alessio, 2016) . Indeed, the GLP-1R is widely expressed in neurons, supporting a role of GLP-1 as a neurotransmitter, locally within the enteric nervous system (ENS) and centrally within the brain, regulating neural circuits controlling metabolic homeostasis (Drucker, 2018b) . A combination of pharmacological studies, optogenetics, chemogenetics, cell ablation, and cell-specific knockdown of the GLP-1R within the CNS implicates multiple neural GLP-1R circuits in the control of food intake, reward, and body weight (Adams et al., 2018; Burmeister et al., 2017; Hayes et al., 2011; Holt et al., 2019; Kanoski et al., 2011; Liu et al., 2017; Ló pez-Ferreras et al., 2018; Sisley et al., 2014) . GLP-1R signaling also controls glucose homeostasis and regulates post-prandial lipoprotein production and secretion through incompletely defined central and/or peripheral neural GLP-1R networks (Farr et al., 2015; Kooijman et al., 2015) .
Interpretation of the sites and mechanisms underlying GLP-1 action requires consideration of the differences in biology of native GLP-1, produced predominantly in the gut and brain, versus the actions emanating from systemic pharmacological administration of GLP-1R agonists. Indeed, GLP-1R agonists are often resistant to enzymatic degradation and circulate at much higher levels with extended pharmacokinetic profiles relative to the low circulating levels of native GLP-1 (Meier, 2012) . Moreover, GLP-1R agonists developed for clinical use exhibit considerable structural heterogeneity, ranging from small peptides to higher-molecular-weight molecules containing GLP-1 epitopes covalently linked to larger proteins (Andersen et al., 2018; Meier, 2012) . These unique structures may contribute to differences in GLP-1R activation or preferential access to Figure 1 . Reduction of Glp1r Levels in Wnt1 + Cells within the Intestine (ENS) and the Brain Does Not Affect Glucose Tolerance, Gastric Emptying, or Food Intake (A-C) Glp1r mRNA abundance (relative to levels of Ppia) was measured in 10-to 15-week-old female Glp1r DWnt1+/+ versus Glp1r DWnt1À/À mice within various ENScontaining (B) , and in the pancreas (expressed relative to control animals [Glp1r DWnt1+/+ ]) (C) (n = 5-10/group). (D and E) Fasting blood glucose, blood glucose excursion, and area under the curve (AUC) over 2 h (D) and plasma levels of total GLP-1, insulin, and glucagon before and 15 min after glucose administration (2 g/kg body weight [BW]) (E) during an oral glucose tolerance test (oGTT) in 6-to 10-month-old Glp1r DWnt1+/+ versus Glp1r DWnt1À/À male mice after a 5-h fast (n = 12-25 animals/group). (F) Blood glucose excursion, AUC over 2 h, and plasma insulin before and 15 min after glucose administration (2 g/kg BW) during an i.p. GTT (ipGTT) in 6-to 10-month-old male Glp1r DWnt1+/+ versus Glp1r DWnt1À/À mice after a 5-h fast. (G) Plasma acetaminophen levels and AUC over 1 h as a measure of gastric emptying in 8-to 10-month-old Glp1r DWnt1+/+ versus Glp1r DWnt1À/À male mice after a 5-h fast and oral administration of glucose (2 mg/kg) and 100 mg/kg BW acetaminophen (1% solution) (n = 12-25 animals/group).
(legend continued on next page) subsets of CNS GLP-1Rs, potentially contributing to the differential efficacy observed in glycemic control, body weight reduction, and cardiovascular outcomes (Andersen et al., 2018; Drucker, 2018a; Meier, 2012) .
To elucidate the importance of specific sites of GLP-1 action relevant for the control of glycemia and food intake, multiple studies have utilized mice and rats treated with GLP-1R antagonists or subjected to cell-and tissue-specific knockdown of the Glp1r in islets and in different regions of the nervous system (Adams et al., 2018; Drucker, 2018b; Hayes et al., 2009; Jessen et al., 2017; Kanoski et al., 2011; Liu et al., 2017; Ló pez-Ferreras et al., 2018; Reiner et al., 2018; Sisley et al., 2014; Smith et al., 2014) . Here we interrogated the metabolic actions of a small peptide GLP-1R agonist, exendin-4, and two larger GLP-1R agonists, albiglutide and dulaglutide, as well as different doses of the DPP-4 inhibitor, sitagliptin in Glp1r DWnt1À/À mice with broad neural inactivation of the Glp1r in cells targeted by expression of the Wnt1-Cre2 promoter within the hypothalamus (Hypo), brain stem (BS), and ENS. Given the potential contribution of neural GLP-1R signaling outside of the brain for control of glycemia and food intake (Grasset et al., 2017; Iwasaki et al., 2018; Kanoski et al., 2011; Krieger et al., 2016) , we also assessed the importance of neural sites for the actions of these incretin agents within regions of the autonomic nervous system targeted by Phox2b, including the dorsal motor nucleus of the vagus (DMV) in parasympathetic visceral and branchial motor neurons, the nodose sensory ganglia, and in cells within the nucleus of the solitary tract (NTS). Simultaneously, we interrogated the importance of these GLP-1R + brain regions for basal control of glycemia, food intake, and gastric emptying in Glp1r DWnt1À/À and Glp1r -D Phox2bÀ/À mice. Finally, we investigated the importance of the GLP-1Rs targeted by Wnt1 and Phox2b for the acute control of basal and GLP-1-regulated lipid metabolism.
RESULTS
Loss of the Glp1r within the Wnt1 + Cellular Domain Does Not Impair Glucose Tolerance or Gastric Emptying Central and peripheral neural GLP-1R circuits control food intake and body weight and have been proposed to control glucose homeostasis (D'Alessio, 2016; Drucker, 2018b) . Less well studied is the extent to which structurally distinct small peptide versus higher-molecular-weight GLP-1R agonists similarly engage GLP-;1Rs within the nervous system to control metabolism. Accordingly, we examined the actions of exendin-4 (a 39-amino acid peptide) and two larger GLP-1R agonists, albiglutide (a cleavage-resistant GLP-1 dimer within the N-terminal domain of human albumin) and dulaglutide (GLP-1(7-37) covalently linked to an Fc fragment of human IgG4). We selected doses of these agents to achieve similar metabolic activities (glucose control, food intake, and lipid tolerance) in acute studies (Figures S1A-S1D).
To evaluate the combined contribution of CNS and ENS GLP-1R + circuits to the acute metabolic actions of GLP-1R agonists, we crossed Glp1r Flox/Flox with Wnt1-Cre2 mice, known to target neurons within the CNS and ENS (described in the STAR Methods; Zhang et al., 2017) , to generate Glp1r DWnt1À/À mice. Glp1r expression was consistently reduced within the muscle layer but not the submucosa or the epithelial mucosa of the small bowel of Glp1r DWnt1À/À mice ( Figure 1A) , with no reduction of Glp1r mRNA transcripts detected in the large bowel ( Figure 1A ). Glp1r mRNA transcripts were also markedly reduced in the BS and hypothalamus; the levels of Glp1r mRNA transcripts within the hippocampus (Hippo), pituitary (Pit), nodose ganglion (NG), and pancreas were unaffected ( Figures 1B and 1C ).
Basal Control of Glucose Tolerance, Food Intake, and Gastric Emptying in Glp1r DWnt1À/À Mice Distinct GLP-1R + neuronal circuits are important for the physiological control of metabolism and also mediate the pharmacological responses to GLP-1R agonism (Drucker, 2018b; Kanoski et al., 2016) ; we therefore analyzed mice in the basal state and following administration of structurally distinct incretin therapies. Reduction of Glp1r expression within Wnt1-Cre2-expressing cells had no effect on fasting blood glucose, oral glucose tolerance ( Figure 1D ), or plasma levels of GLP-1, insulin, or glucagon ( Figure 1E ). Similarly, intraperitoneal (i.p.) glucose tolerance and the associated levels of insulin were not different, although insulin levels trended lower in Glp1r DWnt1À/À mice ( Figure 1F ). Surprisingly, the rates of gastric emptying ( Figure 1G ), food intake over 24 h ( Figures 1H and 1I ), and body weight ( Figure S2J ) were not different in Glp1r DWnt1À/À mice. Hence, simultaneous reduction of hypothalamic, BS, and ENS Glp1r expression is not associated with perturbations in the basal control of glucose homeostasis, gastric emptying, or food intake.
Acute Metabolic Responses to Exendin-4, Albiglutide, and Dulaglutide in Glp1r DWnt1À/À Mice We next assessed the importance of GLP-1R expression within the Wnt1 + domain for the acute metabolic responses arising from pharmacological administration of structurally distinct GLP-1R agonists. The small peptide exendin-4 as well as the higher-molecular-weight GLP-1R agonists albiglutide and dulaglutide improved oral glucose tolerance to a similar extent in Glp1r DWnt1+/+ and Glp1r DWnt1À/À mice (Figure 2A and 2B ). Similarly, exendin-4 enhanced glucose clearance in both genotypes following i.p. administration of glucose ( Figures S3A and S3C ), consistent with functional preservation of GLP-1R within pancreatic b cells (Lamont et al., 2012; Smith et al., 2014) . Interestingly, glucose-stimulated insulin levels were lower in Glp1r DWnt1À/À versus Glp1r DWnt1+/+ mice following exendin-4 administration ( Figure 2C ; Figures S3B and S3D) despite similar glycemic excursion profiles; however, the basal levels of glucagon were not different, and all three GLP-1R agonists reduced plasma glucagon levels to a similar extent following glucose challenge in Glp1r DWnt1+/+ versus Glp1r DWnt1À/À mice ( Figure 2D ).
Loss of GLP-1R within Wnt1 + Cells Impairs the Glycemic Response to Low-Dose Sitagliptin
Considerable pharmacological evidence supports the existence of a gut-brain axis important for transduction of glucoregulatory signals arising from endogenous GLP-1 or gut-selective dosing of DPP-4 inhibitors (Mulvihill et al., 2017; Vahl et al., 2007; Varin et al., 2019; Waget et al., 2011) . Nevertheless, few studies have interrogated the simultaneous importance of GLP-1Rs within the ENS and CNS for control of the gut-brain axis. Although both gut-selective and systemic DPP-4 inhibition with sitagliptin , and glucagon (D) before and 15 min after glucose gavage (2 g/kg BW) during an oGTT in 6-to 10-month-old male Glp1r DWnt1+/+ (n = 21-23/group in A and n = 12-14/group in C and D) and Glp1r DWnt1À/À (n = 12/group in B and n = 6-7/group in C and D) mice after a 5-h fast and in response to PBS, exendin-4 (1 nmol/kg body BW), albiglutide (2 mg/kg BW), or dulaglutide (0.05 mg/kg BW) given just before (exendin-4) or 1 h before (albiglutide and dulaglutide) glucose gavage.
(E-G) Blood glucose and AUC over 2.5 h (E and F) and plasma insulin (G) before and 15 min after glucose gavage (2 g/kg BW) during an oGTT in 6-to 10-month-old male Glp1r DWnt1+/+ (n = 21-23/group in E and n = 12-14/group in G) and Glp1r DWnt1À/À (n = 12/group in F and n = 6-7/group in G) mice administered water or 14 mg/mouse (gut-selective dose) or 10 mg/kg (systemic dose) of sitagliptin 30 min prior to glucose gavage. Data are expressed as means ± SEM. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001 by one-way ANOVA. See also Figures S1 and S3. lowered glycemia and increased plasma insulin levels following oral glucose administration in Glp1r DWnt1+/+ mice ( Figures 2E  and 2G ), the glycemic and insulin responses to gut-selective sitagliptin were abolished in Glp1r DWnt1À/À mice ( Figures 2F  and 2G ).
GLP-1R Agonism Does Not Reduce Food Intake or
Gastric Emptying in Glp1r DWnt1À/À Mice Inhibition of gastric emptying following GLP-1R agonism is thought to involve neural transmission of GLP-1R-dependent sig-nals, in part through the vagus nerve (Charpentier et al., 2018; Plamboeck et al., 2013) . Acute treatment with exendin-4, albiglutide, or dulaglutide reduced gastric emptying in Glp1r DWnt1+/+ but not in Glp1r DWnt1À/À mice ( Figures 3A and 3B ). Furthermore, all three GLP-1R agonists decreased food intake over 24 h in Glp1r DWnt1+/+ mice (Figures 3C and 3D) but not in Glp1r DWnt1À/À mice ( Figures 3E and 3F ). To examine whether GLP-1Rs within the Wnt1 domain were similarly required for weight loss following more sustained GLP-1R agonism, we evaluated the response to dulaglutide administration over 9 days. Glp1r DWnt1+/+ mice
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C D E F G H I Figure 3 . Gastric Emptying, Food Intake, and Weight Loss in Glp1r DWnt1À/À Mice (A and B) Plasma acetaminophen levels (as a measure of gastric emptying) and AUC over 1 h during oGTT and after oral gavage of 100 mg/kg BW acetaminophen (1% solution) in 6-to 10-month-old male Glp1r DWnt1+/+ (A; n = 17-20/group) and Glp1r DWnt1À/À (B; n = 11-12/group) mice after a 5-h fast and in response to PBS, exendin-4 (1 nmol/kg BW), albiglutide (2 mg/kg BW), or dulaglutide (0.05 mg/kg BW) given just before (exendin-4) or 1 h before (albiglutide and dulaglutide) glucose gavage.
(C-F) Non-cumulative food intake (C and E) and 24-h cumulative food intake (D and F) following an overnight fast and i.p. administration of exendin-4 (10 nmol/kg BW just before refeeding), albiglutide (2 mg/kg BW just before fasting), or dulaglutide (0.05 mg/kg BW just before fasting) in 6-to 10-month-old male Glp1r DWnt1+/+ (n = 16/group) and Glp1r DWnt1À/À (n = 12/group) mice. Glp1r DPhox2bÀ/À Mice Exhibit Impaired Glucose Homeostasis and Gastric Emptying Complementary lines of evidence invoke vagal GLP-1Rs as a component of signals necessary for transduction of gut-brain GLP-1 communication and control of glucose homeostasis (Charpentier et al., 2018; Krieger et al., 2016; Plamboeck et al., 2013) . Nevertheless, whether GLP-1Rs within the Phox2b expression domain contribute to basal and GLP-1RA-regulated glucose control and food intake remains uncertain (Sisley et al., 2014) . Accordingly, we used Phox2b-Cre mice, known to target Phox2b + cells within the NG, midbrain, and hindbrain, including the DMV , to selectively attenuate expression of the Glp1r within visceral sensory neurons . No reduction of Glp1r mRNA transcripts was detected in the jejunum, ileum, colon, BS, Hypo, Hippo, Pit, or pancreas from Glp1r DPhox2bÀ/À mice; however, Glp1r mRNA transcripts were not detectable in the NG of Glp1r DPhox2bÀ/À mice ( Figures 4A-4C ). We next interrogated the physiological consequences of disrupting GLP-1 action within cellular domains targeted by Phox2b. Remarkably, Glp1r DPhox2bÀ/À mice exhibited increased fasting levels of glucose, plasma insulin, glucagon, and GLP-1 ( Figure 4D ). No differences were detected in GLP-1 concentration within segments of the small and large bowel ( Figure 4E ), and plasma DPP4 activity was similar in Glp1r DPhox2b+/+ versus Glp1r DPhox2bÀ/À mice ( Figure 4F ). Moreover, Glp1r DPhox2bÀ/À mice exhibited a modest impairment in glycemic excursion following oral glucose ( Figure 4G ) and a marked deterioration in glucose clearance following i.p. glucose challenge despite comparable effects of glucose on the levels of plasma insulin, glucagon, and GLP-1 in both genotypes ( Figures 4H-4J ). Furthermore, gastric emptying was accelerated ( Figure 4K ), and cumulative 24-h food intake was modestly reduced in Glp1r DPhox2bÀ/À mice ( Figures 4L and 4M ). However, the total body weight was not different ( Figure S2K ). Hence, selective reduction of basal GLP-1R signaling within Phox2b-targeted cells, including peripheral sensory neurons, leads to dysregulation of the enteroinsular axis, impaired glucose homeostasis, and gastric motility.
The Phox2b-Targeted Glp1r Is Not Required for the Glucoregulatory Actions of GLP-1R Agonists or the DPP-4 Inhibitor Sitagliptin To ascertain whether Phox2b-targeted GLP-1Rs were similarly important for the metabolic actions of pharmacological GLP-1R agonists, we assessed the actions of exendin-4, albiglutide, and dulaglutide in Glp1r DPhox2bÀ/À mice. All three GLP-1R agonists reduced glycemic excursion to similar levels following oral glucose administration in Glp1r DPhox2b+/+ versus Glp1r DPhox2bÀ/À mice ( Figures 5A and 5B) , accompanied by increased levels of plasma insulin and reduced levels of circulating glucagon ( Figures  5C and 5D) . Similarly, exendin-4 improved glucose tolerance and increased insulin levels in both genotypes in response to i.p. administration of glucose ( Figures S3E-S3H ), consistent with a functional GLP-1R in pancreatic b cells. Furthermore, both gutselective and systemic inhibition of DPP-4 activity with sitagliptin reduced glycemic excursion following oral glucose administration in Glp1r DPhox2b+/+ and Glp1r DPhox2bÀ/À mice ( Figures 5E-5G) . Hence, the GLP-1R within the Phox2b-targeted domain, including the NG, is not required for glucoregulatory responses to GLP-1R agonists or the DPP-4 inhibitor sitagliptin.
Glp1r DPhox2bÀ/À Mice Exhibit Selectively Impaired Responses to GLP-1R Agonists We next examined whether the GLP-1R within domains targeted by Phox2b was required for the reduction of gastric emptying following acute administration of GLP-1R agonists. Exendin-4, albiglutide, and dulaglutide reduced the rate of gastric emptying in Glp1r DPhox2b+/+ mice ( Figure 6A ). Basal gastric emptying was accelerated in Glp1r DPhox2bÀ/À mice (Figure 4K ) and reduced by albiglutide and dulaglutide but not exendin-4 ( Figure 6B ). In contrast, exendin-4 reduced food intake in both Glp1r DPhox2b+/+ and Glp1r DPhox2bÀ/À mice ( Figures 6C-6F) , whereas albiglutide and dulaglutide failed to reduce 24-h cumulative food intake in Glp1r DPhox2bÀ/À mice ( Figures 6E  and 6F ). Consistent with these findings, chronic administration Figure 4 . Glp1r DPhox2bÀ/À Mice Exhibit Altered Glucose Tolerance, Gastric Emptying, and Food Intake (A-C) Glp1r mRNA abundance (relative to Ppia) in tissues from 10-to 15-week-old female Glp1r DPhox2b+/+ versus Glp1r DPhox2bÀ/À mice in various enteric nervous system-containing intestinal compartments (Muc, Mus, and SM) in different regions of the digestive tract (duodenum, jejunum, ileum, and colon) expressed relative to Glp1r mRNA abundance detected in the colon of control animals (Glp1r DPhox2b+/+ ) (A), in different regions of the brain (BS, Hypo, Hippo, Pit, and NG) expressed relative to the BS of control animals (Glp1r DPhox2b+/+ ) (B), and in the pancreas (expressed relative to levels in control animals (Glp1r DPhox2b+/+ ) (C). n = 5-10/group. (D-F) Blood glucose and plasma levels of insulin, glucagon and total GLP-1 (D); levels of active GLP-1 within the different regions of the gut (duodenum [Duo] and jejunum [Jej] (E); and plasma DPP-4 activity (F) in 8-to 10-month-old male Glp1r DPhox2b+/+ and Glp1r DPhox2bÀ/À mice after a 5-h fast (n = 8-18/group). (G and H) Blood glucose and AUC over 2 h (G) and plasma levels of insulin, glucagon, and total GLP-1 before and 15 min after glucose administration (2 g/kg BW) (H) during an oGTT in 6-to 10-month-old male Glp1r DPhox2b+/+ and Glp1r DPhox2bÀ/À mice after a 5-h fast (n = 8-18/group). (I and J) Blood glucose and AUC over 2 h (I) and plasma insulin before and 15 min after glucose administration (2 g/kg BW) (J) during an ipGTT in 8-to 10-monthold male Glp1r DPhox2b+/+ and Glp1r DPhox2bÀ/À mice after a 5-h fast (n = 8-18/group). (K) Plasma acetaminophen levels (as a measure of gastric emptying) and AUC over 1 h during oGTT and after oral gavage of 100 mg/kg BW acetaminophen (1% solution) in 6-to 10-month-old male Glp1r DPhox2b+/+ and Glp1r DPhox2bÀ/À mice after a 5-h fast (n = 15/group). (L and M) Non-cumulative (L) and cumulative (M) food intake over 24 h after refeeding following an overnight fast in 6-to 10-month-old male Glp1r DPhox2b+/+ and Glp1r DPhox2bÀ/À mice (n = 15/group). Data are expressed as means ± SEM. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001 by t test (B, D, G, I, and K-M) or two-way ANOVA (H and J). See also Figure S2 . (legend continued on next page) of dulaglutide was associated with attenuated weight loss in Glp1r DPhox2bÀ/À versus Glp1r DPhox2b+/+ mice ( Figures 6G-6I ).
Glp1r DWnt1À/À and Glp1r DPhox2bÀ/À Mice Exhibit Normal Lipid Tolerance and Preserved Hypolipidemic Responses to GLP-1R Agonism GLP-1R agonists have been postulated to inhibit post-prandial lipoprotein production and secretion through central and/or peripheral neural GLP-1R networks (Farr et al., 2015; Kooijman et al., 2015) . We therefore evaluated triglyceride excursion in response to an oral gavage of olive oil in the presence or absence of acute GLP-1R agonists. Triglyceride excursions following oral olive oil administration were not different in Glp1r DWnt1À/À and Glp1r DPhox2bÀ/À versus littermate control mice ( Figures 7A  and 7B ). Moreover, all three structurally distinct GLP-1R agonists reduced triglyceride excursions in Glp1r DWnt1À/À and Glp1r DPhox2bÀ/À mice and their respective controls ( Figures  7C-7F ). Hence, GLP-1R expression within the broad neuronal domains targeted by Wnt1-Cre2 and GLP-1R + neurons targeted by Phox2b-Cre is not required for GLP-1R-dependent inhibition of triglycerides following oral lipid challenge.
DISCUSSION
GLP-1 exerts a broad range of metabolic activities, encompassing control of glycemia, reduction of food intake, and inhibition of gut motility, actions supporting the development of GLP-1R agonists for the treatment of type 2 diabetes and obesity Sandoval and D'Alessio, 2015) . The CNS actions of small peptide GLP-1R agonists have been associated with direct access to hypothalamic and hindbrain GLP-1R + neurons (Knudsen and Lau, 2019; Secher et al., 2014) . Although we initially hypothesized that larger GLP-1R agonists such as albiglutide and dulaglutide might exhibit slightly less effective activation of neural GLP-1R + circuits regulating gastric emptying or food intake, our experimental pharmacology results did not reveal broad differences in the acute metabolic actions of structurally distinct GLP-1R agonists. The extent to which basal GLP-1R signaling within distinct cell compartments is physiologically essential for acute versus longterm control of glucose homeostasis and body weight is more controversial and depends on the experimental context. Glp1r À/À mice exhibit impaired glucose tolerance (Scrocchi et al., 1996) , and selective deletion or restoration of the GLP-1R within murine b cells of Glp1r À/À mice reveals an essential role for the b cell GLP-1R in glucose homeostasis (Lamont et al., 2012; Smith et al., 2014) . The relative importance of the GLP-1R for control of murine body weight, as revealed through genetic approaches, reflects the experimental paradigm. Mice with germline deletion of the Glp1r in the C57BL/6 background resist development of diet-induced obesity and insulin resistance, in part because of upregulation of locomotor activity and energy expenditure (Ayala et al., 2010; Hansotia et al., 2007; Scrocchi et al., 1996) . In contrast, glucose tolerance and body weight were not different in Glp1r DNestinÀ/À mice with widespread reduction of CNS Glp1r expression (Sisley et al., 2014) , and selective targeting of hypothalamic Glp1r expression did not identify a subset of hypothalamic GLP-1R + neurons essential for the control of body weight or glucose homeostasis (Burmeister et al., 2017) .
On the other hand, transient central or peripheral pharmacological antagonism of the GLP-1R led to increased food intake and more significant weight gain in rats and mice (Meeran et al., 1999; Patterson et al., 2011) . Similarly, postnatal inactivation of the Glp1r within the hypothalamus increased food intake and weight gain (Liu et al., 2017) , and selective reduction of GLP-1R activity within different regions of the rat brain impaired the control of either food intake, meal size, body weight, energy expenditure, or adiposity (Alhadeff et al., 2017; Lee et al., 2018; Ló pez-Ferreras et al., 2018) . Our current findings of normal glucose tolerance, food intake, and gastric emptying in Glp1r DWnt1À/À mice provide further evidence that germline reduction of hypothalamic, BS, and ENS Glp1r expression in mice does not markedly perturb basal control of glucose or food intake or the acute glucoregulatory response to exogenous GLP-1R agonists. Nevertheless, exogenous administration of GLP-1R agonists failed to reduce food intake (and gastric emptying) in Glp1r DWnt1À/À mice. These findings are consistent with the marked simultaneous reduction of hypothalamic and BS Glp1r mRNA transcripts and reflect the importance of multiple neural hypothalamic and BS GLP-1R + populations for the pharmacological control of GLP-1-regulated feeding (Burmeister et al., 2017; Hayes et al., 2011; Sisley et al., 2014) .
A considerable body of evidence also supports the functional importance of a gut-brain axis, whereby intestinal GLP-1 activates neural circuits both external to and within the CNS to control glucose metabolism (Burcelin et al., 2014) . Nevertheless, the precise cellular location of GLP-1R + neurons critical for transduction of these physiological signals remains uncertain. Previous studies have revealed that gut-selective potentiation of endogenous incretin action, achieved through reduction of intestinal but not systemic DPP-4 activity, is partially attenuated following GLP-1R pharmacological blockade or whole-body inactivation of the Glp1r (Mulvihill et al., 2017; Waget et al., 2011) . Indeed, high-fat diet feeding to reduce ENS Glp1r expression, subdiaphragmatic vagotomy, and administration of cis-platinum to induce ENS neuropathy were all associated with relative GLP-1 resistance and impairment of the GLP-1gut-brain axis (Grasset et al., 2017; Kanoski et al., 2011) . Here we further localize the GLP-1R + populations transducing the glucoregulatory actions of intestine-selective DPP-4 inhibition to those targeted by Wnt1-Cre2, as the metabolic effects of low-dose intestine-selective sitagliptin were completely attenuated in Glp1r DWnt1À/À mice. These findings are consistent with (E-G) Glucose and AUC over 2.5 h (E and F, n = 12-18/group) and insulin (G, n = 6-15/group) before and 15 min after glucose administration (2 g/kg BW) during an oGTT (5-h fast) in 6-to 10-month-old male Glp1r DPhox2b+/+ and Glp1r DPhox2bÀ/À mice administered water or 14 mg/mouse (gut-selective dose) or 10 mg/kg (systemic dose) of sitagliptin 30 min prior to glucose gavage. Data are expressed as means ± SEM. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001 by one-way ANOVA. See also Figures S1 and S3 . the marked reduction in small bowel Glp1r expression within the muscular layer of Glp1r DWnt1À/À mice, an anatomical site with ENS localization of GLP-1Rs (Grasset et al., 2017; Wismann et al., 2017) . In contrast, selective DPP-4 inhibition with low-dose sitagliptin maintained glucoregulatory activity in Glp1r DPhox2bÀ/À mice.
Surprisingly, selective loss of the GLP-1R in Glp1r DPhox2bÀ/À mice resulted in increased levels of fasting glycemia, impaired glucose tolerance, accelerated gastric emptying, and increased levels of GLP-1, insulin, and glucagon. Indeed, these striking findings are consistent with observations in rats with lentiviral vector-mediated knockdown of the NG Glp1r, resulting in elevated post-meal glycemia and accelerated gastric emptying (Krieger et al., 2016) . Notably, increased circulating levels of GLP-1, insulin, C-peptide, and glucagon and increased rates of gastric emptying were also observed in humans following truncal vagotomy (Plamboeck et al., 2013) . Equally unexpected was our finding that the extent of dulaglutide-induced weight loss was diminished in Glp1r DPhox2bÀ/À mice, implicating the GLP-1R within the Phox2b expression domain as yet another contributor to signals regulating the pharmacological GLP-1R-dependent control of body weight. These results are consistent with data demonstrating diminished reduction of food intake in rats with subdiaphragmatic vagal deafferentation Figure 6 . Gastric Emptying, Food Intake, and Weight Loss Responses to GLP-1R Agonists in Glp1r DPhox2bÀ/À Mice (A and B) Plasma acetaminophen levels (as a measure of gastric emptying) and AUC over 1 h during oGTT and after oral gavage of 100 mg/kg BW acetaminophen (1% solution) in 6-to 10-month-old male Glp1r DPhox2b+/+ (A, n = 16/group) and Glp1r DPhox2bÀ/À (B, n = 13/group) mice after a 5-h fast and in response to i.p. administration of PBS, exendin-4 (1 nmol/kg BW), albiglutide (2 mg/kg BW), or dulaglutide (0.05 mg/kg BW) given just before (exendin-4) or 1 h before (albiglutide and dulaglutide) glucose gavage.
(C-F) Non-cumulative food intake (C and E) and 24-h cumulative food intake (D and F) after re-feeding following an overnight fast in response to i.p. administration of exendin-4 (10 nmol/kg BW just before refeeding), albiglutide (2 mg/kg BW just before fasting), or dulaglutide (0.05 mg/kg BW just before fasting) in 6-to 10-month-old male Glp1r DPhox2b+/+ and Glp1r DPhox2bÀ/À mice (n = 15-16/group).
(G-I) Change in body weight (G and H) and cumulative body weight loss (I) during 9 days of treatment with PBS or dulaglutide (0.5 mg/kg BW) every other day in 6-to 10-month-old male Glp1r DPhox2b+/+ (n = 12-14/group) and Glp1r DPhox2bÀ/À (n = 5-6/group) mice. Arrows represent i.p. injections of PBS or dulaglutide. Data are expressed as means ± SEM. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001 by one-way ANOVA. See also Figure S1 .
the inhibitory actions of GLP-1 on food intake in human subjects after vagotomy (Plamboeck et al., 2013) . Collectively, these findings reveal essential physiological roles of GLP-1R expression within Phox2b + vagal sensory afferents, including the NG, in the control of GLP-1 levels, islet hormones, and glucose tolerance and establish the GLP-1Rs within the Phox2b domain as essential for a component of the weight loss response ensuing following sustained GLP-1R agonism. GLP-1R agonists also rapidly reduce plasma levels of postprandial triglycerides in mice and humans, actions mediated by the canonical GLP-1R (Hsieh et al., 2010; Xiao et al., 2012) . Indeed, plasma levels of TG-rich lipoproteins are higher after olive oil challenge in Glp1r À/À mice (Hsieh et al., 2010) , consistent with the importance of basal GLP-1R signaling for either triglyceride production, secretion, and/or clearance. Although the precise GLP-1R + cell types mediating the hypolipidemic actions of GLP-1 remain unclear, several studies implicated neural GLP-1 receptors in GLP-1R-dependent control of triglyceride-rich lipoproteins (Burmeister et al., 2012; Farr et al., 2015; Kooijman et al., 2015) . Nevertheless, we did not observe any perturbation of triglyceride excursion following oral olive oil administration in Glp1r DWnt1À/À and Glp1r DPhox2bÀ/À mice. Furthermore, although GLP-1R agonists lost their ability to reduce gastric emptying in Glp1r DWnt1À/À mice, the reduction of acute triglyceride excursion following administration of exendin-4, albiglutide, or dulaglutide was preserved in Glp1r DWnt1À/À and Glp1r DPhox2bÀ/À mice. Hence, the GLP-1R + cell type(s) essential for transduction of the rapid (within minutes) triglyceride-lowering actions of GLP-1R agonist administration are distinct from those controlling food intake and gastric emptying and not targeted by Wnt1-Cre2 or Phox2b-Cre. The putative identity and importance of neural sites transducing the acute hypolipidemic actions of GLP-1R agonists remain uncertain.
Our studies have a number of important limitations. First, we assessed the phenotypes of Glp1r DWnt1À/À and Glp1r DPhox2bÀ/À Figure 7 . GLP-1R Agonists Reduce Triglyceride Excursions in Glp1r DWnt1À/À and Glp1r DPhox2bÀ/À Mice (A-F) Plasma triglycerides (TGs) over a 3-h period after oral gavage with olive oil (200 mL/mouse) during a lipid tolerance test in 5-h-fasted, 9-to 13-month-old male Glp1r DWnt1+/+ versus Glp1r DWnt1À/À (A, C, and E) or Glp1r DPhox2b+/+ versus Glp1r DPhox2bÀ/À (B, D, and F) mice basally (A and B) or in response to i.p. administration of PBS, exendin-4 (1 nmol/kg BW just before olive oil gavage), albiglutide (2 mg/kg BW 16 h before olive oil gavage), or dulaglutide (0.05 mg/kg BW just before fasting) (C-F), (n = 9-25 animals / group). Data are expressed as means ± SEM. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001 by one-way ANOVA. See also Figure S1 . mice with germline inactivation of the Glp1r in multiple neuronal populations and, hence, cannot rule out modification of one or more metabolic phenotypes as a result of adaptation to embryonic or developmental loss of the GLP-1R. Second, the majority of our assessments, principally of glucose homeostasis, gastric emptying, food intake, and triglyceride excursion, were acute and may not reflect the biology of the GLP-1R within these neural circuits over more prolonged periods of assessment. Third, we studied regular chow-fed mice without experimental diabetes or obesity, and resistance to GLP-1 action under these circumstances (Grasset et al., 2017) might alter future conclusions from studies conducted under different metabolic conditions. Fourth, we chose doses of exendin-4, albiglutide, and dulaglutide based on their equivalent pharmacodynamic activity in acute glucose tolerance tests, and it remains possible that a different dosing paradigm would yield experimental results with alternative conclusions. Fifth, Wnt1 and Phox2b direct Cre expression to multiple GLP-1R + sites, precluding definitive assignment of specific cellular GLP-1Rs to individual phenotypes described here. Nevertheless, our studies are in agreement with but extend concepts invoking multiple central and peripheral neuronal GLP-1R + populations required for GLP-1R agonism to control food intake and body weight. Furthermore, our current findings elevate the importance of the GLP-1R within the Phox2b domain as an essential sensor of physiological peptidergic signals, linking basal GLP-1R signaling to the control of L cell and islet hormone secretion, gastric emptying, and glucose homeostasis.
In summary, our findings provide evidence that germline disruption of the Glp1r within the cellular domains (including the enteric and central nervous system) targeted by Wnt1-Cre2 does not impair basal control of food intake, body weight, gastric emptying, or glucose homeostasis. Nevertheless, these same GLP-1R + populations are essential for transducing the pharmacological responses to small and larger GLP-1R agonists in control of food intake, body weight, and gastric emptying but not required for GLP-1R-dependent regulation of glucose homeostasis. Furthermore, neural GLP-1Rs targeted by Wnt1-Cre2 are essential for transduction of a glucoregulatory and islet response to low dose sitagliptin, further highlighting the importance of the gut-brain axis for conveying metabolic signals originating from gut-selective potentiation of incretin action.
Equally compelling are insights gleaned from our studies of Glp1r DPhox2bÀ/À mice, demonstrating that GLP-1Rs within the Phox2b expression domain are essential for basal control of gastric emptying, food intake, glucose tolerance, and circulating levels of insulin and glucagon in response to glucose challenge. In contrast, these Phox2b + GLP-1R + cellular domains are not required for the pharmacological actions of GLP-1R agonists to control glucose or lipid homeostasis. Collectively, these findings further emphasize the divergence in functional GLP-1R + populations controlling physiological actions of endogenous GLP-1 versus pharmacological responses to GLP-1R agonism and identify key neuronal populations essential for the transduction of gut-derived GLP-1R signals important for control of glucose homeostasis.
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